最近来自俄勒冈州立大学和Aradigm生物技术公司的科学家成功完成了利用载药系统递送ciproflaxcin治疗肺部感染的研究。这种名为Lipoquin的新药是以脂质体的形式包载抗生素，当患者吸入这些药物颗粒时，药物会在肺部缓慢释放，一方面能提高药效，另一方面能防止药物对身体其他正常组织的毒害作用。目前这种药物被设计用来治疗与囊胞性纤维症、慢性阻塞性肺炎等疾病相关的感染。数据显示，在体外实验中，200mcg/ml的高剂量治疗四天可降低感染99%左右，而20mcg/ml的低剂量组也表现出良好的治疗效果；而对照组的未包载ciproflaxacin却未表现出同样疗效。
目前公司已经完成了临床二期研究，公司拟在今年上半年开展Lipoquin的临床三期研究。
A team of scientists from Oregon State University (OSU) and Aradigm, a small pulmonary device company out of California, touted successful in vitro results for its inhaled, encapsulated ciproflaxacin treatment for lung infections.
The liposomal formulation, Lipoquin, is a vesicle made from lipids to encapsulate drugs, which are then slowly released in the lungs when they're inhaled. This sustained delivery keeps the treatment at the intended site without causing problems elsewhere in the body.
Ciproflaxacin is commonly used in oral and intravenous formulations as an antibiotic. Aradigm's Pulmaquin, on the other hand, is a dual-release formulation of both Lipoquin and free ciproflaxacin that can be delivered directly to the lungs to treat infections associated with cystic fibrosis, chronic obstructive pulmonary disease and alpha-1 antitrypsin deficiency. The company has brought it through a Phase IIb study and plans to begin a Phase III trial in the first half of this year. Aradigm also received orphan status for Pulmaquin in the U.S.
Aradigm's liposomal ciproflaxacin demonstrated in vitro to decrease 99% of infections in macrophages at a high concentration of 200 mcg/ml over four days, according to a company release. At a smaller concentration of 20 mcg/ml, the treatment still showed a 70% decrease of Mycobacterium avium and 90% decrease of Mycobacterium abscessus. Comparatively, unencapsulated ciproflaxacin did not show a significant decrease of either infection.
"These results are very encouraging as the current treatments are not particularly effective and have many side effects," said lead researcher Luiz Bermudez from OSU. "The airway delivery of ciproflaxacin in a vehicle that shows capability of killing specific mycobacteria harbored in macrophages and biofilms may be a promising way to help patients with these debilitating chronic infections."
The team will present the data in May at the American Thoracic Society's 2014 International Conference.
免责声明：
本文仅供专业人士学术交流探讨，不作为诊疗及用药依据。
如有侵权，请联系我们删除